Tianjin Lisheng PharmaceuticalLtd Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Fujun Wang
Chief executive officer
CN¥1.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 7.8yrs |
| CEO ownership | 0.02% |
| Management average tenure | 4.5yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
CEO
Fujun Wang (56 yo)
7.8yrs
Tenure
CN¥1,026,000
Compensation
Mr. Fujun Wang has been a Non-Independent Director of Tianjin Lisheng Pharmaceutical Co.,Ltd. since August 17, 2017 and serves as its General Manager.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Non-Independent Director | no data | CN¥1.03m | 0.022% CN¥ 953.0k | |
| Financial Director | 3.6yrs | CN¥602.30k | 0.017% CN¥ 762.4k | |
| Secretary of the Board | 11.4yrs | CN¥718.50k | 0.017% CN¥ 762.4k | |
| Chief Engineer & Deputy GM | 5.3yrs | CN¥802.20k | 0.017% CN¥ 762.4k | |
| Deputy General Manager | 2.7yrs | CN¥528.50k | 0.017% CN¥ 762.4k | |
| Deputy General Manager | no data | CN¥729.20k | 0.017% CN¥ 762.4k |
4.5yrs
Average Tenure
49.5yo
Average Age
Experienced Management: 002393's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Non-Independent Director | 7.8yrs | CN¥1.03m | 0.022% CN¥ 953.0k | |
| Director | 2yrs | CN¥781.70k | 0.017% CN¥ 762.4k | |
| Non-Independent Director | 3.3yrs | no data | no data | |
| Independent Director | 3.4yrs | CN¥60.00k | no data | |
| Independent Director | 4.4yrs | CN¥60.00k | no data | |
| Independent Director | 4.4yrs | CN¥60.00k | no data | |
| Supervisor | 2.8yrs | no data | no data | |
| Chairman of the Board | 2.5yrs | CN¥833.00k | 0.022% CN¥ 953.0k | |
| Director | 2yrs | no data | no data | |
| Chairman of the Board of Supervisors | 2yrs | no data | no data | |
| Director | 2.8yrs | no data | no data | |
| Supervisor | 2.1yrs | no data | no data |
2.8yrs
Average Tenure
52yo
Average Age
Experienced Board: 002393's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 15:02 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tianjin Lisheng Pharmaceutical Co.,Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peng Yan | Changjiang Securities Co. LTD. |
| Jie Yao | Everbright Securities Co. Ltd. |
| Ting Huang | Sinolink Securities Co., Ltd. |